Esperion Therapeutics Inc. (NASDAQ:ESPR) price closed lower on Monday, April 15, dropping -9.58% below its previous close.
A look at the daily price movement shows that the last close reads $2.14. The company’s 5Y monthly beta was ticking 0.82. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.40 and 52-week low of $0.70. The stock subtracted -5.61% on its value in the past month.
Esperion Therapeutics Inc., which has a market valuation of $329.76 million, is expected to release its quarterly earnings report May 07, 2024 – May 13, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give ESPR a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.
The overview shows that ESPR’s price is at present -24.62% off the SMA20 and -22.80% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 34.45, with weekly volatility standing at 13.76%. The indicator jumps to 12.62% when calculated based on the past 30 days. Esperion Therapeutics Inc. (NASDAQ:ESPR)’s beta value is holding at 0.86, while the average true range (ATR) indicator is currently reading 0.30.
An analysis of the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock in terms of its daily trading volume indicates that the 3-month average is 6.74 million.
Current records show that the company has 170.42M in outstanding shares. The insiders’ percentage holdings are 1.10% of outstanding shares while the percentage share held by institutions stands at 48.11%. But the -35.28% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
